Featured Research

from universities, journals, and other organizations

Synthetic gene circuits pump up cell signals in study of neurodegenerative diseases

Date:
April 8, 2014
Source:
Rice University
Summary:
Synthetic genetic circuitry created by researchers is helping them monitor cell mechanisms that degrade the misfolded proteins implicated in neurodegenerative diseases. Scientists have designed a sophisticated circuit that signals increases in the degradation of proteins by the cell's ubiquitin proteasome system.

The Deg-On system, an engineered regulator, controls the expression of a fluorescent reporter. Activation of the ubiquitin proteasome system (UPS) enhances degradation of the regulator and leads to an increase in fluorescent output. Tetracycline, an inducer, can be used to fine-tune the system and optimize detection of different levels of UPS activation.
Credit: Segatori Group/Rice University

Synthetic genetic circuitry created by researchers at Rice University is helping them see, for the first time, how to regulate cell mechanisms that degrade the misfolded proteins implicated in Parkinson's, Huntington's and other diseases.

The Rice lab of chemical and biomolecular engineer Laura Segatori has designed a sophisticated circuit that signals increases in the degradation of proteins by the cell's ubiquitin proteasome system (UPS).

The research appears online today in Nature Communications.

The UPS is essential to a variety of fundamental cellular processes, including the cell cycle, DNA repair, immune response, cell death and the degradation of misfolded and damaged proteins. It has several components: ubiquitin molecules that tag misfolded proteins for degradation and proteasomes that latch onto the tagged proteins and break them down into harmless peptides.

When there are too few proteasomes in a cell, or they don't function properly, misfolded proteins that remain floating in the cytoplasm can aggregate. These aggregates can form plaques, as often seen in the brains of people with neurodegenerative diseases.

The Rice team added to the cell a set of genetic circuits called Degradation On -- "Deg-On" for short. These circuits produce a green fluorescent signal linked to UPS degradation and allow the researchers to monitor proteasomal activity.

"The overall goal is to develop a technology to screen for molecules that would enhance or activate degradation," said Segatori, Rice's T.N. Law Assistant Professor of Chemical and Biomolecular Engineering and an assistant professor of biochemistry and cell biology.

"The proteasome is essentially a big barrel that unfolds and chops up misfolded proteins. We know how to inhibit degradation, but we want to find ways to activate it, because we think that will be useful to help prevent accumulation of misfolded proteins and aggregation, which are associated with the development of a number of human diseases."

The Deg-On circuit couples proteasomal degradation of an engineered tetracycline repressor to an easily detectable fluorescent signal. The tetracycline repressor is engineered to function as a UPS substrate; it essentially mimics a misfolded protein.

Normally, enhanced degradation would dampen the output signal, but this genetic circuit makes it possible to link enhanced degradation to an increase in output. The engineered repressor can still be regulated by the antibiotic tetracycline, which allows calibrating the system for the detection of even minimal activation of UPS degradation. An additional synthetic circuit provides a feedback loop that enables the self-amplification of the repressor so that adding tetracycline further boosts the signal.

The Rice team did extensive computer modeling of Deg-On to improve its sensitivity and dynamic range before building and testing the system on lab-standard HeLa cells. The team included graduate student and lead author Wenting Zhao, undergraduate Claire McWhite and Rice alumnus Matthew Bonem, in collaboration with Jonathan Silberg, an associate professor of biochemistry and cell biology at Rice.

"We came up with the idea of having a feedback loop, which is a self-activation loop for the tetracycline repressor, in our second circuit (an enhanced Deg-On)," Zhao said. "We found that a small increase in UPS activity caused a small decrease in the TetR repressor protein. Because TetR activates its own expression in the enhanced Deg-On, the fluorescent output signal is amplified and the circuit gains in sensitivity and dynamic range."

"Wenting's work was instrumental in predicting changes in the circuit architecture that would lead to enhanced sensitivity," Segatori said.

The lab's immediate goal is to create assays for the rapid detection of small molecules or genes that can increase proteasomal activity, she said. "This will help us rationally design compounds or strategies that could enhance degradation not only for the study and treatment of misfolding diseases but also for a variety of other applications.

"Misfolding and aggregation are among the main challenges in the fields of bioengineering and biotechnology. They are the bottleneck in the high-yield production of recombinant proteins, for example, in cells engineered to crank up expression of a protein of interest," Segatori said.

The National Science Foundation, the Welch Foundation and the Sid W. Richardson Foundation, through a Rice Institute of Biosciences and Bioengineering Medical Innovations Award Grant, supported the research.


Story Source:

The above story is based on materials provided by Rice University. The original article was written by Mike Williams. Note: Materials may be edited for content and length.


Journal Reference:

  1. Wenting Zhao, Matthew Bonem, Claire McWhite, Jonathan J. Silberg, Laura Segatori. Sensitive detection of proteasomal activation using the Deg-On mammalian synthetic gene circuit. Nature Communications, 2014; 5 DOI: 10.1038/ncomms4612

Cite This Page:

Rice University. "Synthetic gene circuits pump up cell signals in study of neurodegenerative diseases." ScienceDaily. ScienceDaily, 8 April 2014. <www.sciencedaily.com/releases/2014/04/140408112212.htm>.
Rice University. (2014, April 8). Synthetic gene circuits pump up cell signals in study of neurodegenerative diseases. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/04/140408112212.htm
Rice University. "Synthetic gene circuits pump up cell signals in study of neurodegenerative diseases." ScienceDaily. www.sciencedaily.com/releases/2014/04/140408112212.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins